ACCESSWIRE
United States
Tel: 1-888-952-4446
Website: https://www.accesswire.com/
Email: DigitalSales@accesswire.com
About ACCESSWIRE
ACCESSWIRE is a global newswire and communications network, delivering regional, national and international news to thousands of customers across the world. ACCESSWIRE serves both public and private companies, disseminating their full-text and rich media press releases to news media, financial markets, investors, information websites, databases, bloggers and social networks.
The press release platform offers an exceptionally cost-effective Fair Disclosure, Regulation FD news dissemination and media outreach service.
Platform users can easily publish rich media assets, such as video, audio and images, and build their own distribution to the most-needed outlets. Users can effectively distribute an earnings announcement, product launch, community message, M&A transaction or corporate update to the worldwide news network.
Corporate issuers and their constituents find the cloud-based platforms and related services particularly robust — from document creation through dissemination to regulatory bodies, platforms and shareholders.
Contact ACCESSWIRE’s parent company, Issuer Direct, to learn more.
6069 articles about ACCESSWIRE
-
Salix Will Present XIFAXAN(R) (Rifaximin), TRULANCE(R) (Plecanatide) and RELISTOR(R) (Methylnaltrexone Bromide) Data at The American College of Gastroenterology(R) 2022 Annual Scientific Meeting
10/24/2022
Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals today announced four posters and one abstract featuring data for XIFAXAN (rifaximin), TRULANCE (plecanatide) and RELISTOR (methylnaltrexone bromide) that are being presented at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting.
-
Dr. Sigurd Berven to join Aclarion as a Key Opinion Leader Surgeon Advisor
10/24/2022
Aclarion, Inc. announced today that Sigurd Berven M.D., Chief of Spine Service, Orthopaedic Surgery at University of California at San Francisco will advise the company as a key opinion leader (KOL) nationally.
-
Angle PLC Announces Parsortix Poster Presented at ISLB Meeting
10/24/2022
ANGLE plc, a world-leading liquid biopsy company, is pleased to announce it presented results from a proof of concept study at the International Society of Liquid Biopsy meeting in Miami, Florida on 20-22 October 2022.
-
9 Meters Biopharma Presents Preclinical Data on Glucose-Dependent Insulinotropic Polypeptide (GIP) Monoclonal Antibodies for Obesity at the American College of Gastroenterology 2022 Annual Scientific Meeting
10/24/2022
9 Meters Biopharma, Inc. delivered two poster presentations at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting, taking place in Charlotte, North Carolina, on October 21-26, 2022.
-
Media Alert: BrainChip Exhibits its Essential AI Capabilities at the Linley Fall Processor Conference 2022
10/23/2022
BrainChip Holdings Ltd, the world's first commercial producer of ultra-low power neuromorphic AI IP, announced that Chief Development Officer Anil Mankar will present "System-Level Advances in Neuromorphic Performance, Efficiency, Configurability and Scalability" at the Linley Fall Processor Conference 2022 in the Hyatt Regency Hotel in Santa Clara, California, November 1 at 10 a.m. PDT.
-
XVIVO Perfusion AB: Conference Call on Interim Report
10/21/2022
XVIVO Perfusion AB Invitation to attend XVIVO's conference call regarding the presentation of the interim report January-September 2022.
-
Statera Biopharma Files Form 10-Q and Reaches Agreement with Silverback Capital and AVOF
10/21/2022
Statera Biopharma, Inc., a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced that the Company filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 with the Securities and Exchange Commission.
-
Angle PLC Announces Issue of Equity - October 21, 2022
10/21/2022
ANGLE plc, a world-leading liquid biopsy company, announces that following the exercise of employee options, it has issued and allotted 25,000 new ordinary shares of £0.10 each in the Company.
-
Petros Pharmaceuticals to Participate in Two October 2022 Conferences
10/21/2022
Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a leading provider of therapeutics for men's health, announces today that President and Chief Commercial Officer Fady Boctor will participate in two October 2022 conferences.
-
MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
10/21/2022
MorphoSys AG reported preliminary Monjuvi® U.S. net product sales for the third quarter of 2022 and provided an update to its financial guidance for 2022. Preliminary Monjuvi ® U.S. Net Product Sales are US$ 22.2 million for the third quarter of 2022 and US$ 64.1 million for the first nine months of 2022.
-
AlzeCure Presents New Data with its Preventive Treatment Alzstatin at the Alzheimer Conference CTAD
10/20/2022
AlzeCure Pharma announced that an abstract with new preclinical Alzstatin data has been accepted for presentation at the annual Alzheimer conference CTAD, Clinical Trials in Alzheimer's Disease, which this year is being held in San Francisco on November 29 - December 2.
-
NovAccess Global Announces Fireside Chat with Board Member Perspectives
10/20/2022
NovAccess Global Inc., a biomedical company developing novel immunotherapies for brain tumor patients, announced the availability of its initial installment in a series of interviews with its corporate leadership on a monthly basis for the next four months, with additional sessions to be made available as company developments arise.
-
Nomination Committee Appointed for the 2023 Annual General Meeting in Spago Nanomedical
10/20/2022
Spago Nanomedical In accordance with a resolution at Spago Nanomedical AB's Annual General Meeting on May 18, 2022, a Nomination Committee for the 2023 Annual General Meeting has been appointed.
-
Biovica Appoints Anders Morén as CFO
10/20/2022
Biovica International Biovica, active in cancer diagnostics, announces that Anders Morén has been appointed as the company's Chief Financial Officer.
-
Ortho Dermatologics To Present New Data at the 2022 Fall Clinical Dermatology Conference
10/20/2022
Bausch Health Companies Inc. today announced the presentation of eleven posters during the Fall Clinical Dermatology Conference, which takes place Oct. 20-23, 2022 in Las Vegas, Nev.
-
Naltrexone Demonstrates Promising Long COVID Application
10/20/2022
LOVE Pharma Co., the Company having announced its nonbinding Letter of Intent to acquire Naltrexone Therapeutics Inc., on October 11th, is pleased to share that Naltrexone has been identified to show promise in treatment of long COVID.
-
NuGen M.D. Announces the Launch of its InsuJet(TM) Needle-Free Injection Device in Canada
10/19/2022
NuGen Medical Devices Inc. is pleased to announce the official launch of its InsuJet devices in Canada.
-
EMA Committee for Medicinal Products for Human Use Issues Positive Opinion Recommending Authorization for the Use of Spikevax (mRNA-1273) in Children 6 Months - 5 Years in the European Union
10/19/2022
Moderna, Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending a variation to the conditional marketing authorization to include a 25 µg two-dose series of Spikevax for active immunization to prevent coronavirus disease 2019 caused by SARS-CoV-2 in children 6 months to 5 years.
-
Biovica Submits CLIA Lab Application for DiviTum(R)TKa Launch
10/19/2022
Biovica International Biovica announces that the company has submitted its CLIA lab application, marking yet another significant milestone for the US commercial launch of the recent FDA cleared test DiviTum®TKa.
-
Rho Appoints Clinical Oncologist and Industry Veteran J. Marc Pipas, MD, As Senior Medical Director
10/19/2022
Rho, a full-service contract research organization with a proven track record of drug development success, announced the appointment of J. Marc Pipas, MD, a leading oncologist, as Senior Medical Director.